Earlier this year, Purespring announced that the European Medicines Agency (EMA) had granted orphan drug designation to PS-002 for the treatment of patients with IgAN. This designation followed the ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a ...

NMRA-861 has demonstrated a potentially best-in-class pharmacological profile and robust activity in preclinical efficacy models. NMRA-861 was safe and well-tolerated in pre-clinical toxicology ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

The live webcast will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should ...

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in ...

HAE Attack Rates in Pediatric Patients 2 to <12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P; Poster #13 (encore from AAAAI / WAO 2025) BioCryst President and ...

During his tenure as CEO, Dr. Houston has been instrumental in Arvinas’ success moving six programs into the clinic, reporting the results of the first positive pivotal Phase 3 trial for a PROTAC, and ...